MCID: INS001
MIFTS: 61

Insulinoma malady

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Insulinoma

Aliases & Descriptions for Insulinoma:

Name: Insulinoma 38 12 50 56 29 52 42 14 69
Islet Cell Adenoma 12 69
Experimental Organism Islet Cell Adenoma Neoplasm 69
Insulin-Producing Tumor of Islet Cells 12
Adenoma Islet Cell 52
Islet Cell Tumor 69

Characteristics:

Orphanet epidemiological data:

56
insulinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Ireland),1-9/1000000 (Worldwide),1-9/1000000 (Japan); Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:3892
Orphanet 56 ORPHA97279
MESH via Orphanet 43 D007340
UMLS via Orphanet 70 C0021670
ICD10 via Orphanet 34 E16.8

Summaries for Insulinoma

NIH Rare Diseases : 50 insulinoma is a type of pancreatic neuroendocrine tumor (pancreatic net), which refers to a group of rare tumors that form in the hormone-making cells of the pancreas. insulinomas, specifically, produce too much insulin, a hormone that reduces the level of sugar in the blood by helping it move into cells. as a result, people with insulinomas generally have very low blood sugar levels which can be associated with anxiety, confusion, hunger, a fast heart rate, and sweating. in severe cases, it can lead to seizures, coma or even death. ninty percent of insulinomas are benign (noncancerous). in most cases, the underlying cause of insulinoma is unknown. however, people with specific genetic syndromes such as multiple endocrine neoplasia type i, von hippel-lindau syndrome, neurofibromatosis type 1, and tuberous sclerosis are at risk of insulinomas and other endocrine tumors. treatment generally includes surgery to remove the tumor. last updated: 4/26/2016

MalaCards based summary : Insulinoma, also known as islet cell adenoma, is related to metastatic insulinoma and adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia, and has symptoms including fatigue, seizures and tremor. An important gene associated with Insulinoma is INSM1 (INSM Transcriptional Repressor 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Presynaptic function of Kainate receptors. The drugs Liver Extracts and pancreatic polypeptide have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and heart, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 An adenoma that is located in the pancreas and is characterized by overproduction of insulin.

Wikipedia : 71 An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a... more...

Related Diseases for Insulinoma

Diseases related to Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
id Related Disease Score Top Affiliating Genes
1 metastatic insulinoma 11.9
2 adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia 11.8
3 pancreatitis 10.5
4 hypoglycemia 10.4
5 retinal melanoma 10.3 INSM1 PTPRN
6 posterior myocardial infarction 10.2 INSM1 PTPRN
7 paranasal sinus cancer, adult 10.2 INS MEN1 SST
8 pemphigus foliaceus 10.2 MEN1 SST
9 paroxysmal nonkinesigenic dyskinesia 2 10.2 INS PTPRN
10 urethra clear cell adenocarcinoma 10.2 INS MEN1 SST
11 multiple endocrine neoplasia 10.2
12 tabes dorsalis 10.2 MEN1 SCT SST
13 secondary syphilis 10.2 CHGA SST
14 microphthalmia, syndromic 8 10.2 GCG INS
15 thrombophilia 10.2 INS MEN1 SST
16 retinal vascular occlusion 10.2 INS SCT SST
17 brain edema 10.2 CHGA SST
18 uterine ligament cancer 10.1 MEN1 SST
19 hepatitis 10.1
20 fibrosis of extraocular muscles, congenital, 3c 10.1 PDX1 SCT
21 choline deficiency disease 10.1 INS SST
22 spinal stenosis 10.1 CHGA INS SST
23 antidepressant type abuse 10.1 GCK INS PTPRN
24 mitochondrial complex ii deficiency 10.1 CHGA MEN1 SST
25 cowden syndrome 3 10.1 CHGA MEN1 SST
26 cardioauditory syndrome of sanchez cascos 10.1 CHGA MEN1 SST
27 gmppa-cdg 10.1 CHGA SCT SST
28 hepatitis b reinfection following liver transplantation 10.1 CHGA MEN1 SST
29 parathyroid carcinoma 10.1 CHGA MEN1 SCT
30 adult ependymoblastoma 10.1 CHGA MEN1
31 diaphanospondylodysostosis 10.0 ABCC8 GCK
32 shaken baby syndrome 10.0 INS SST
33 neutropenia, severe congenital, 5, autosomal recessive 10.0 CHGA MEN1 SST
34 nosophobia 10.0 ABCC8 GCK
35 glucagonoma 10.0
36 keloids 10.0 CHGA INS MEN1 SST
37 vestibular gland benign neoplasm 10.0 CHGA INS MEN1 SST
38 labyrinthine unilateral reactive loss 10.0 ABCC8 GCK INS
39 endocrine gland cancer 10.0 CHGA MEN1 SST
40 progressive relapsing multiple sclerosis 10.0 CHGA MEN1 SCT SST
41 leukemia, acute promyelocytic, somatic 10.0 CHGA MEN1 SCT SST
42 peripheral degeneration of cornea 10.0 GCG INS SCT SST
43 gastrinoma 10.0
44 obesity 10.0
45 alopecia-mental retardation syndrome 2 9.9 ABCC8 INS SLC2A2
46 gemistocytic astrocytoma 9.9 GCG MEN1 SCT SST
47 blind loop syndrome 9.9 GCG GCK INS
48 epilepsy 9.9
49 duodenitis 9.9
50 acute pyelonephritis 9.9 CHGA INS MEN1 SCT SST

Graphical network of the top 20 diseases related to Insulinoma:



Diseases related to Insulinoma

Symptoms & Phenotypes for Insulinoma

Human phenotypes related to Insulinoma:

56 32 (show all 35)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Occasional (29-5%) HP:0012378
2 seizures 56 32 Very frequent (99-80%) HP:0001250
3 tremor 56 32 Very frequent (99-80%) HP:0001337
4 lethargy 56 32 Occasional (29-5%) HP:0001254
5 generalized muscle weakness 56 32 Frequent (79-30%) HP:0003324
6 hyperhidrosis 56 32 Very frequent (99-80%) HP:0000975
7 abnormality of vision 56 32 Occasional (29-5%) HP:0000504
8 hearing abnormality 56 32 Occasional (29-5%) HP:0000364
9 anxiety 56 32 Occasional (29-5%) HP:0000739
10 paresthesia 56 32 Occasional (29-5%) HP:0003401
11 neuroendocrine neoplasm 56 32 Occasional (29-5%) HP:0100634
12 coma 56 32 Occasional (29-5%) HP:0001259
13 hyperinsulinemic hypoglycemia 56 32 Very frequent (99-80%) HP:0000825
14 zollinger-ellison syndrome 56 32 Frequent (79-30%) HP:0002044
15 pituitary prolactin cell adenoma 56 32 Frequent (79-30%) HP:0006767
16 fasting hyperinsulinemia 56 32 Very frequent (99-80%) HP:0008283
17 increased body weight 56 32 Frequent (79-30%) HP:0004324
18 insomnia 56 32 Occasional (29-5%) HP:0100785
19 polyphagia 56 32 Frequent (79-30%) HP:0002591
20 neoplasm of the adrenal gland 56 32 Occasional (29-5%) HP:0100631
21 recurrent hypoglycemia 56 32 Very frequent (99-80%) HP:0001988
22 nonketotic hypoglycemia 56 32 Very frequent (99-80%) HP:0001958
23 palpitations 56 32 Very frequent (99-80%) HP:0001962
24 reactive hypoglycemia 56 32 Frequent (79-30%) HP:0012051
25 transient global amnesia 56 32 Very frequent (99-80%) HP:0010534
26 primary hyperparathyroidism 56 32 Frequent (79-30%) HP:0008200
27 abnormality of the pancreatic islet cells 56 32 Very frequent (99-80%) HP:0006476
28 fluctuations in consciousness 56 32 Frequent (79-30%) HP:0007159
29 abnormality of pain sensation 56 32 Occasional (29-5%) HP:0010832
30 reduced consciousness/confusion 56 Frequent (79-30%)
31 behavioral abnormality 56 Frequent (79-30%)
32 hyperinsulinemia 56 Very frequent (99-80%)
33 abnormality of higher mental function 56 Occasional (29-5%)
34 abnormal rapid eye movement (rem) sleep 56 Occasional (29-5%)
35 abnormal rapid eye movement sleep 32 HP:0002494

MGI Mouse Phenotypes related to Insulinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.9 ABCC8 CHGA GCK GLP1R INS INSM1
2 growth/size/body region MP:0005378 9.7 INSM1 MEN1 PDX1 SLC2A2 SST WFS1
3 homeostasis/metabolism MP:0005376 9.5 GCK GLP1R IAPP INS INSM1 KCNA5

Drugs & Therapeutics for Insulinoma

Drugs for Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
2 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
7
Exenatide Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 141758-74-9 15991534
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
11 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
12 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
16 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
17 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hypoglycemic Agents Phase 2, Phase 3,Phase 1,Early Phase 1
20 Incretins Phase 2, Phase 3,Phase 1,Early Phase 1
21 Calcimimetic Agents Phase 3
22 Calcium, Dietary Phase 3,Phase 2,Phase 1
23 Cinacalcet Hydrochloride Phase 3
24 Adjuvants, Anesthesia Phase 3
25 Analgesics Phase 3
26 Analgesics, Opioid Phase 3
27 Anesthetics Phase 3
28 Anesthetics, General Phase 3
29 Anesthetics, Intravenous Phase 3
30 Central Nervous System Depressants Phase 3
31 Narcotics Phase 3
32 Peripheral Nervous System Agents Phase 3
33 Folate Nutraceutical Phase 2, Phase 3
34 Vitamin B9 Nutraceutical Phase 2, Phase 3
35 Cola Nutraceutical Phase 3,Phase 2,Phase 1
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
41
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
42
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Streptozocin Approved Phase 2 18883-66-4 29327
45
Melphalan Approved Phase 2 148-82-3 4053 460612
46
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
47
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
48
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
49
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
50
Glycerol Approved, Experimental Phase 2 56-81-5 753

Interventional clinical trials:

(show all 48)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
3 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells Recruiting NCT02127541 Phase 2, Phase 3
6 Effect of Gelofusine on GLP1-receptor Imaging Completed NCT02541734 Phase 1, Phase 2
7 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
8 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
9 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
10 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
11 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
12 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
13 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
14 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
15 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
16 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2
17 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
18 Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes Active, not recruiting NCT00336674 Phase 2
19 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2
20 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2
21 Reversing Type 1 Diabetes After it is Established Active, not recruiting NCT01106157 Phase 1, Phase 2
22 Pasireotide in Hyperinsulinemic Hypoglycemia Not yet recruiting NCT03053284 Phase 2
23 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2
24 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2
25 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
26 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2
27 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
28 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2
29 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
30 Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients Completed NCT00937079 Phase 1
31 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
32 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
33 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
34 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
35 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
36 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
37 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
38 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
39 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
40 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
41 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis Unknown status NCT02560376 Early Phase 1
42 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Unknown status NCT00730483
43 Laparoscopy to Remove Pancreatic Tumors (Insulinomas) Completed NCT00005910
44 Diagnosing and Treating Low Blood Sugar Levels Recruiting NCT00001276
45 EUS-guided Ethanol Ablation of an Insulinoma Active, not recruiting NCT02121366
46 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia Available NCT01916148
47 18F-FDOPA PET in Neuroendocrine Tumours Available NCT02431715
48 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893

Search NIH Clinical Center for Insulinoma

Cochrane evidence based reviews: insulinoma

Genetic Tests for Insulinoma

Genetic tests related to Insulinoma:

id Genetic test Affiliating Genes
1 Insulinoma 29

Anatomical Context for Insulinoma

MalaCards organs/tissues related to Insulinoma:

39
Pancreas, Heart, Testes, Pancreatic Islet, Liver, Eye, Pituitary

The Foundational Model of Anatomy Ontology organs/tissues related to Insulinoma:

18
The Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Insulinoma:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease

Publications for Insulinoma

Articles related to Insulinoma:

(show top 50) (show all 897)
id Title Authors Year
1
A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. ( 27908529 )
2017
2
Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma. ( 28230660 )
2017
3
Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. ( 28071719 )
2017
4
A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. ( 27984486 )
2017
5
Insulinoma Detection With MDCT: Is There a Role for Whole-Pancreas Perfusion? ( 27929662 )
2017
6
Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy. ( 28458908 )
2017
7
Baicalein protects rat insulinoma INS-1 cells from palmitate-induced lipotoxicity by inducing HO-1. ( 28445528 )
2017
8
Characteristics of glucose metabolism indexes and continuous glucose monitoring system (CGMS) in patients with insulinoma. ( 28293303 )
2017
9
Endoscopic Ultrasound-Guided Ethanol Ablation for Control of Local-Regional Metastatic Insulinoma. ( 28187109 )
2017
10
Geniposide improves insulin production and reduces apoptosis in high glucose-induced glucotoxic insulinoma cells. ( 28363490 )
2017
11
Insulinoma - The incremental value of somatostatin receptor positron emission tomography. ( 28217530 )
2017
12
T372R Mutation Status in Yin Yang 1 Gene in Insulinoma Patients. ( 28472826 )
2017
13
Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. ( 28508501 )
2017
14
Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma. ( 28225059 )
2017
15
Hypoglycemia identified by a continuous glucose monitoring system in a second-trimester pregnant woman with insulinoma: a case report. ( 28427440 )
2017
16
Paroxysmal Hypertension Induced by an Insulinoma. ( 28202863 )
2017
17
Seizures Due to Insulinoma- A Rare but Treatable Cause. ( 28462560 )
2017
18
Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection. ( 28419614 )
2017
19
Small pancreatic insulinoma: Successful endoscopic ultrasound-guided radiofrequency ablation in a single session using a 22-G fine needle. ( 28295664 )
2017
20
Sporadic Insulinoma as a Rare Cause of Recurrent Hypoglycemia in Children. ( 28512591 )
2017
21
Postprandial hypoglycemia as the only manifestation of insulinoma: exceptional case report. ( 28416239 )
2017
22
Development of (111)In-labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma. ( 28089587 )
2017
23
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application. ( 27881117 )
2016
24
Microcystin-LR induces dysfunction of insulin secretion in rat insulinoma (INS-1) cells: Implications for diabetes mellitus. ( 27107231 )
2016
25
Concomitant Insulinoma and Type 2 Diabetes Mellitus Diagnoses: A Case Report. ( 27075402 )
2016
26
Insulinoma After Bariatric Surgery: Diagnostic Dilemma and Therapeutic Approaches. ( 26846121 )
2016
27
Non-insulinoma Pancreatogeneous Hypoglycemia Syndrome with False-Positive Somatostatin Receptor Scintigraphy: A Case Report and Review of Literature. ( 27276748 )
2016
28
Liver Metastases 10 Years after Resection of a "Benign" Insulinoma. ( 28206926 )
2016
29
Glycemic control in patients with insulinoma. ( 28222404 )
2016
30
Expression of the insulinoma-associated 1 (insm1) gene in Xenopus laevis tadpole retina and brain. ( 27670931 )
2016
31
Giant insulinoma in a 15-year-old man: A case report. ( 27258815 )
2016
32
Recurrent Seizures Due to Pancreatic Insulinoma. ( 27739279 )
2016
33
Diagnosis of insulinoma using the ratios of serum concentrations of insulin and C-peptide to glucose during a 5-hour oral glucose tolerance test. ( 27725372 )
2016
34
Insulinoma due to multiple pancreatic microadenoma localized by multimodal imaging. ( 27504852 )
2016
35
The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition. ( 27221730 )
2016
36
The role of endosomal cholesterol trafficking protein, StAR-related lipid transfer domain 3 (StarD3/MLN64), in BRIN-BD11 insulinoma cells. ( 27679500 )
2016
37
Giant Malignant Insulinoma. ( 26969167 )
2016
38
A Case of 36-Year-Old Woman With Recurrent Hypoglycemia Due to Insulinoma With Cytokeratin-19 Expression: A Marker of Poor Prognosis. ( 26752258 )
2016
39
Focal hepatic glycogenosis associated with metastatic insulinoma presenting as mass lesions. ( 26627264 )
2016
40
Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilemma. ( 27887024 )
2016
41
P-selectin-mediated LOX expression promotes insulinoma growth in Rip1-Tag2 mice by increasing tissue stiffness. ( 27877081 )
2016
42
Multiple Endocrine Neoplasia Type 1 Presenting as Hypoglycemia due to Insulinoma. ( 27247513 )
2016
43
DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-I_B activation. ( 27612849 )
2016
44
Erratum to: Uptake of a fluorescent L-glucose derivative 2-NBDLG into three-dimensionally accumulating insulinoma cells in a phloretin-sensitive manner. ( 26886928 )
2016
45
Giant insulinoma: report of a case and review of published reports. ( 27864816 )
2016
46
Insulinoma Causing Prolonged Hypoglycaemic Coma. ( 27656487 )
2016
47
Operation for insulinomas in multiple endocrine neoplasia type 1: When pancreatoduodenectomy is appropriate. ( 27863775 )
2016
48
Tumor-specific promoter-driven adenoviral therapy for insulinoma. ( 26902080 )
2016
49
Diagnostic Difficulties in a Pediatric Insulinoma: A Case Report. ( 26986124 )
2016
50
Tumor Heterogeneity Detected by 68Ga DOTATOC and 18F-FDG PET/CTs in One Malignant Insulinoma With Involvement of the Portal Splenic Confluence and Ovarian Metastases. ( 27607168 )
2016

Variations for Insulinoma

Expression for Insulinoma

Search GEO for disease gene expression data for Insulinoma.

Pathways for Insulinoma

Pathways related to Insulinoma according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1 12.26 GCG INS PDX1 WFS1
2
Show member pathways
12.13 GCG GLP1R IAPP SCT
3
Show member pathways
12.1 ABCC8 GCG GCK GLP1R INS PDX1
4
Show member pathways
12.08 ABCC8 GCG GLP1R INS SLC2A2
5 11.87 GCG GLP1R IAPP SCT
6
Show member pathways
11.76 GCK INS PDX1 SLC2A2
7 11.65 GCG GCK SLC2A2
8
Show member pathways
11.64 ABCC8 GCK INS PDX1 SLC2A2
9
Show member pathways
11.1 GCK IAPP INS INSM1 PDX1 SLC2A2
10 11 ABCC8 GCK INS PDX1 SLC2A2
11 10.68 INS SLC2A2

GO Terms for Insulinoma

Cellular components related to Insulinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 9.33 CHGA PTPRN PTPRN2
2 transport vesicle membrane GO:0030658 9.13 CHGA PTPRN PTPRN2
3 endoplasmic reticulum lumen GO:0005788 9.02 GCG INS MEN1 PTPRN2 WFS1

Biological processes related to Insulinoma according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.8 IAPP INS MEN1 WFS1
2 glucose metabolic process GO:0006006 9.65 GCK INS PDX1
3 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.56 PDX1 WFS1
4 cellular glucose homeostasis GO:0001678 9.55 ABCC8 GCK
5 positive regulation of glycogen biosynthetic process GO:0045725 9.54 GCK INS
6 negative regulation of gluconeogenesis GO:0045721 9.52 GCK INS
7 regulation of potassium ion transport GO:0043266 9.51 GCK KCNA5
8 glucose transport GO:0015758 9.5 GCK INS SLC2A2
9 negative regulation of vasodilation GO:0045908 9.46 CHGA INS
10 glucose homeostasis GO:0042593 9.46 GCK INS PDX1 WFS1
11 transdifferentiation GO:0060290 9.43 INSM1 PDX1
12 insulin secretion involved in cellular response to glucose stimulus GO:0035773 9.4 PTPRN PTPRN2
13 negative regulation of type B pancreatic cell apoptotic process GO:2000675 9.37 PDX1 WFS1
14 detection of glucose GO:0051594 9.26 GCK PDX1
15 type B pancreatic cell differentiation GO:0003309 9.13 INSM1 MEN1 PDX1
16 regulation of insulin secretion GO:0050796 9.1 ABCC8 GCG GCK GLP1R KCNA5 SLC2A2

Molecular functions related to Insulinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 GCG IAPP INS SCT SST

Sources for Insulinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....